Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MAIN STUDY: Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? SUB-STUDY: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide

NCT01970410 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT01970410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01970410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MAIN STUDY: Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? SUB-STUDY: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide
Lead sponsor
Providence Health & Services
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2013
Completion date
February 14, 2022
Enrollment
55 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis